Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q2 2022 Results - Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET

Company Participants

Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications

Yvonne Greenstreet – Chief Executive Officer

Tolga Tanguler – Chief Commercial Officer

Akshay Vaishnaw – President

Jeff Poulton – Chief Financial Officer

Conference Call Participants

Paul Matteis – Stifel

David Lebowitz – Citi

Salveen Richter – Goldman Sachs

Ritu Baral – Cowen

Tazeen Ahmad – Bank of America

Joseph Stringer – Needham

Maury Raycroft – Jefferies

Luca Issi – RBC Capital

Gary Nachman – BMO

Anupam Rama – J.P. Morgan

Gena Wang – Barclays

Eliana Merle – UBS

Myles Minter – William Blair

Olivia Brayer – Cantor

Operator

Hello, thank you for standing by. And welcome to the Alnylam Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference may be recorded. [Operator Instructions]

I would now like to hand the conference over to the company. Please go ahead.

Christine Lindenboom

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Akshay Vaishnaw, President; and Jeff Poulton, Chief Financial Officer.

For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During today’s call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Akshay will review recent clinical and preclinical updates. And Jeff will review our financials and guidance, followed by a summary of our upcoming milestones before we open the call for your questions.

Please note we are in a quite period with regards to the upcoming APOLLO-B results and therefore will not be addressing any questions on that matter.

I would like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans and prospects which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file with the SEC.